{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:48:17Z","timestamp":1782301697988,"version":"3.54.5"},"reference-count":21,"publisher":"Gobierno de Navarra","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/deed.es"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An Sist Sanit Navar"],"abstract":"<jats:p>Introducci\u00f3n. La pauta habitual de linezolid se asocia con exposici\u00f3n sub\u00f3ptima en pacientes cr\u00edticos. En este estudio se analiza la asociaci\u00f3n entre las distintas modalidades de tratamiento (dosis, tiempo de infusi\u00f3n) y la probabilidad de alcanzar los objetivos farmacocin\u00e9ticos\/farmacodin\u00e1micos, evaluando su impacto microbiol\u00f3gico y cl\u00ednico.\nPacientes y m\u00e9todos. Estudio retrospectivo en pacientes ingresados en unidades de cuidados intensivos con monitorizaci\u00f3n terap\u00e9utica de linezolid entre mayo de 2021 y diciembre de 2023. Se analiz\u00f3 el cumplimiento de los objetivos farmacocin\u00e9ticos\/farmacodin\u00e1micos (Cmin: 2-7 mg\/L, AUC: 0\u201324\/CMI: 80\u2013120 mg*h\/L, y T&gt;CMI \u226585%) en funci\u00f3n de la pauta inicial (1.200 o 1.800 mg\/d\u00eda) y tiempo de infusi\u00f3n (1 o 3 h). Se analizaron subgrupos de riesgo: obesidad, aclaramiento de creatinina aumentado, t\u00e9cnicas de reemplazo renal y &lt;65a\u00f1os\nResultados. Se incluyeron 70 pacientes. En la primera monitorizaci\u00f3n, el 18,6% alcanz\u00f3 los tres objetivos farmacocin\u00e9ticos\/farmacodin\u00e1micos y el 40% tuvo la Cmin en rango. No hubo diferencias estad\u00edsticamente significativas en la consecuci\u00f3n de objetivos seg\u00fan la pauta o el tiempo de infusi\u00f3n (tampoco en subgrupos de riesgo). Sin embargo, el cumplimiento de Cmin fue superior con la dosis de 1.800 mg\/d\u00eda (54,5% vs. 37,3%). Tampoco se detectaron diferencias significativas respecto a resultados microbiol\u00f3gicos y cl\u00ednicos seg\u00fan Cmin estuviese en rango o no.\nConclusiones. Menos del 20% de pacientes alcanz\u00f3 todos los objetivos farmacocin\u00e9ticos\/farmacodin\u00e1micos con la pauta inicial. Estos resultados sugieren la necesidad de individualizar y monitorizar las pautas para optimizar el tratamiento en esta poblaci\u00f3n, especialmente en perfiles de riesgo.<\/jats:p>","DOI":"10.23938\/assn.1151","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:42:20Z","timestamp":1774960940000},"page":"e1151","source":"Crossref","is-referenced-by-count":0,"title":["Consecuci\u00f3n de objetivos farmacocin\u00e9ticos\/farmacodin\u00e1micos en pacientes cr\u00edticos con monitorizaci\u00f3n terap\u00e9utica de linezolid","Achievement of pharmacokinetic\/pharmacodynamic targets with linezolid therapeutic drug monitoring in critically ill patients"],"prefix":"10.23938","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-4899","authenticated-orcid":false,"given":"Irati","family":"Irigoyen Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2272-7086","authenticated-orcid":false,"given":"Leire","family":"Leache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4435-2780","authenticated-orcid":false,"given":"Julen","family":"Fern\u00e1ndez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Eg\u00fces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Librero L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10024","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. ABDUL-AZIZ MH, ALFFENAAR JC, BASSETTI M, BRACHT H, DIMOPOULOS G, MARRIOTT D et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic\/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med 2020;46(6):1127-1153. https:\/\/doi.org\/10.1007\/s00134-020-06050-1","DOI":"10.1007\/s00134-020-06050-1"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. HASHEMIAN SMR, FARHADI T, GANJPARVAR M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther 2018;12:1759-1767. https:\/\/doi.org\/10.2147\/DDDT.S164515","DOI":"10.2147\/DDDT.S164515"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. MA A, DONG M, CHENG J, LIAO X, DONG W, LIU C et al. Clinical efficacy and safety of linezolid in intensive care unit patients. J Intensive Med 2022;3(1):65-72. https:\/\/doi.org\/10.1016\/j.jointm.2022.05.006","DOI":"10.1016\/j.jointm.2022.05.006"},{"key":"ref3","unstructured":"4. Centro de Informaci\u00f3n Online de Medicamentos de la AEMPS (CIMA). Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS): Acceso el 3 de junio de 2024.https:\/\/cima.aemps.es\/cima\/publico\/home.html"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. KOCH BCP, MULLER AE, HUNFELD NGM, DE WINTER BCM, EWOLDT TMJ, ABDULLA A et al. Therapeutic drug monitoring of antibiotics in critically ill patients: current practice and future perspectives with a focus on clinical outcome. Ther Drug Monit 2022;44(1):11-18. https:\/\/doi.org\/10.1097\/FTD.0000000000000942","DOI":"10.1097\/FTD.0000000000000942"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. BAND\u00cdN-VILAR E, GARC\u00cdA-QUINTANILLA L, CASTRO-BALADO A, ZARRA-FERRO I, GONZ\u00c1LEZ-BARCIA M, CAMPOS-TOIMIL M et al. A review of population pharmacokinetic analyses of linezolid. Clin Pharmacokinet 2022;61(6):789-817. DOI: 10.1007\/s40262-022-01125-2","DOI":"10.1007\/s40262-022-01125-2"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. VIAGGI B, CANGIALOSI A, LANGER M, OLIVIERI C, GORI A, CORONA A et al. Tissue penetration of antimicrobials in intensive care unit patients: a systematic review-Part II. Antibiotics (Basel) 2022;11(9):1193. https:\/\/doi.org\/10.3390\/antibiotics11091193","DOI":"10.3390\/antibiotics11091193"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. ZOLLER M, MAIER B, HORNUSS C, NEUGEBAUER C, D\u00d6BBELER G, NAGEL D et al. Variability of linezolid concentrations after standard dosing in critically ill patients: A prospective observational study. Crit Care 2014;18(4):1-11. https:\/\/doi.org\/10.1186\/cc13984","DOI":"10.1186\/cc13984"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. WANG X, WANG Y, YAO F, CHEN S, HOU Y, ZHENG Z et al. Pharmacokinetics of linezolid dose adjustment for creatinine clearance in critically ill patients: a multicenter, prospective, open-label, observational study. Drug Des Devel Ther 2021;15:2129-2141. https:\/\/doi.org\/10.2147\/DDDT.S303497","DOI":"10.2147\/DDDT.S303497"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. XU Y, YANG X, LIANG P, QU C. Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more. BMC Infect Dis 2023;23(1):840. https:\/\/doi.org\/10.1186\/s12879-023-08831-7","DOI":"10.1186\/s12879-023-08831-7"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. DOU L, MENG D, DONG Y, CHEN L, HAN X, FAN D et al. Dosage regimen and toxicity risk assessment of linezolid in sepsis patients. Int J Infect Dis 2020;96:105-111. https:\/\/doi.org\/10.1016\/j.ijid.2020.03.054","DOI":"10.1016\/j.ijid.2020.03.054"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. SORALUCE A, BARRASA H, AS\u00cdN-PRIETO E, S\u00c1NCHEZ-IZQUIERDO J\u00c1, MAYNAR J, ISLA A et al. Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation. Pharmaceutics 2020;12(1):1-13. https:\/\/doi.org\/10.3390\/pharmaceutics12010054","DOI":"10.3390\/pharmaceutics12010054"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. TAUBERT M, ZANDER J, FRECHEN S, SCHARF C, FREY L, VOGESER M et al. Optimization of linezolid therapy in the critically ill: The effect of adjusted infusion regimens. J Antimicrob Chemother 2017;72(8):2304-2310. https:\/\/doi.org\/10.1093\/jac\/dkx149","DOI":"10.1093\/jac\/dkx149"},{"key":"ref13","unstructured":"14. GUTI\u00c9RREZ S\u00c1NCHEZ JA, HERN\u00c1NDEZ S\u00c1NCHEZ M, MANRESA RAM\u00d3N N, N\u00c1JERA P\u00c9REZ MD. An\u00e1lisis de niveles plasm\u00e1ticos de linezolid en pacientes criticos. ILAPHAR 2024 (first online)."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. HUI LA, BODOLEA C, VLASE L, HIRISCAU EI, POPA A. Linezolid administration to critically ill patients: intermittent or continuous infusion? A systematic literature search and review. Antibiotics 2022;11(4):436. https:\/\/doi.org\/10.3390\/antibiotics11040436","DOI":"10.3390\/antibiotics11040436"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. HEIDARI S, KHALILI H. Linezolid pharmacokinetics: a systematic review for the best clinical practice. Eur J Clin Pharmacol 2023;79(2):195-206. https:\/\/doi.org\/10.1007\/s00228-022-03446-4","DOI":"10.1007\/s00228-022-03446-4"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. ADEMBRI C, FALLANI S, CASSETTA MI, ARRIGUCCI S, OTTAVIANO A, PECILE P et al. Linezolid pharmacokinetic\/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008;31(2):122-129. https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.09.009","DOI":"10.1016\/j.ijantimicag.2007.09.009"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. EL-GAML RM, EL-KHODARY NM, ABOZAHRA RR, EL-TAYAR AA, EL-MASRY SM. Applying pharmacokinetic\/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence. Eur J Clin Pharmacol 2022;78(8):1301-1310. https:\/\/doi.org\/10.1007\/s00228-022-03340-z","DOI":"10.1007\/s00228-022-03340-z"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. ABOU WARDA AE, SARHAN RM, AL-FISHAWY HS, MOHARRAM AN, SALEM HF. Continuous versus intermittent linezolid infusion for critically ill patients with hospital-acquired and ventilator-associated pneumonia: efficacy and safety challenges. Pharmaceuticals 2022;15(3):296. https:\/\/doi.org\/10.3390\/ph15030296","DOI":"10.3390\/ph15030296"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. WICHA SG, MAIR A, CHIRIAC U, FREY OR, FUCHS T, GAASCH M et al. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients. Int J Antimicrob Agents 2022;59(5):106572. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106572","DOI":"10.1016\/j.ijantimicag.2022.106572"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. DE PASCALE G, FORTUNA S, TUMBARELLO M, CUTULI SL, VALLECOCCIA M, SPANU T et al. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intensive Care Med 2015;41(1):103-110. https:\/\/doi.org\/10.1007\/s00134-014-3550-y","DOI":"10.1007\/s00134-014-3550-y"}],"container-title":["Anales del Sistema Sanitario de Navarra"],"original-title":[],"link":[{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/download\/113736\/87488","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/download\/113736\/87488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:03:36Z","timestamp":1782299016000},"score":1,"resource":{"primary":{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/113736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,10]]}},"URL":"https:\/\/doi.org\/10.23938\/assn.1151","relation":{},"ISSN":["2340-3527","1137-6627"],"issn-type":[{"value":"2340-3527","type":"electronic"},{"value":"1137-6627","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}